Marine Drugs in Cell Signaling Pathways 2nd Edition

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2271

Special Issue Editors


E-Mail Website
Guest Editor
Department of Mdicine, University of Alberta, Edmonton, AB, Canada
Interests: natural product chemistry; medicinal chemistry; biochemistry; functional food; marine algae utilization; sulfated polysaccharides; sarcopenia–obesity–inflammation; wastewater chemistry; food chemistry; environmental chemistry; particulate matter
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
3-18D Agriculture/Forestry Centre, University of Alberta, Edmonton, AB, Canada
Interests: marine natural products; medicinal chemistry; bioprospecting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine organisms are a valuable source of bioactive metabolites with great potential to revolutionize modern medicine and biotechnology. Specialized metabolites, also known as bioactive secondary metabolites, are molecules that are not essential for the organism's growth or survival but play a crucial role in ecological interactions and defense mechanisms. These include, but are not limited to: polyphenols (such as a diverse array of phlorotannins, phenolic acids, and their halogenated derivatives), sulfated polysaccharides, hydrocolloids, numerous glycosides, polyunsaturated fatty acids, and terpenoids (including carotenoids, sterols, meroditerpenes, alkaloids, mycosporine-like amino acids, and peptides). Marine specialized metabolites have been found to exhibit a broad range of biological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, and immunomodulatory effects, which encourage their sustainable utilization as marine drugs.

This Special Issue aims to showcase the latest developments in marine specialized metabolites, focusing on their isolation, purification, characterization, bioactivity evaluation, and application in various fields. Additionally, it intends to highlight the current state-of-the-art research in specialized metabolism and the potential of marine specialized metabolites in drug discovery, pharmaceuticals, and cosmeceuticals, with special attention to cell signaling pathways.

We welcome high-quality reviews and research articles on the range of topics mentioned above. We look forward to receiving contributions that advance our understanding of marine specialized metabolites and their role in mediating multiple disorders through the sustainable utilization of abundant marine natural sources.

Dr. Thilina U. Jayawardena
Dr. I. P. Shanura Fernando
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine resources
  • drugs
  • natural products
  • marine bioresource technology
  • medicinal chemistry
  • cell signaling pathways
  • inflammation
  • apoptosis
  • obesity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4424 KiB  
Article
Resistomycin Inhibits Wnt/β-Catenin Signaling to Induce the Apoptotic Death of Human Colorectal Cancer Cells
by Yaoyao Zhu, E Zhang, Huan Gao, Chuangeng Shang, Mengxiong Yin, Mingtao Ma, Yu Liu, Xuanfeng Zhang and Xia Li
Mar. Drugs 2023, 21(12), 622; https://doi.org/10.3390/md21120622 - 29 Nov 2023
Cited by 5 | Viewed by 1914
Abstract
Resistomycin is a natural antibiotic related to quinone that has been shown to exhibit robust antitumor activity. To further characterize the mechanistic basis for such activity, human colorectal cancer (CRC) cells were selected as a model to explore the role of Wnt/β-catenin signaling [...] Read more.
Resistomycin is a natural antibiotic related to quinone that has been shown to exhibit robust antitumor activity. To further characterize the mechanistic basis for such activity, human colorectal cancer (CRC) cells were selected as a model to explore the role of Wnt/β-catenin signaling in the ability of resistomycin to induce apoptotic cell death. These analyses revealed that resistomycin was able to suppress β-catenin, TCF4, and GSK-3β expression, together with that of the downstream targets c-Myc and survivin. This coincided with elevated cleaved caspase-3 and Bax protein levels and a decline in Bcl-2 content. When β-catenin was silenced, this further enhanced the ability of resistomycin to induce apoptotic CRC cell death, whereas this apoptotic process was partially ablated when cells were treated using lithium chloride to activate Wnt/β-catenin signaling. Overall, these results support a model wherein resistomycin inhibits Wnt/β-catenin signaling within CRC cells, thereby inducing apoptotic death. Further research may be warranted to better clarify the potential utility of this compound as a candidate drug for use in the treatment of patients suffering from this form of cancer. Full article
(This article belongs to the Special Issue Marine Drugs in Cell Signaling Pathways 2nd Edition)
Show Figures

Figure 1

Back to TopTop